Business Description
Sonoma Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US83558L3033
Total Employee Number:
168Description
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.85 | |||||
Equity-to-Asset | 0.22 | |||||
Debt-to-Equity | 0.27 | |||||
Debt-to-EBITDA | -0.36 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -18.64 | |||||
Beneish M-Score | -1.31 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -47 | |||||
3-Year EBITDA Growth Rate | 62.5 | |||||
3-Year EPS without NRI Growth Rate | 60.4 | |||||
3-Year FCF Growth Rate | 59.8 | |||||
3-Year Book Growth Rate | -62.4 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.8 | |||||
9-Day RSI | 34.76 | |||||
14-Day RSI | 40.4 | |||||
3-1 Month Momentum % | 7.69 | |||||
6-1 Month Momentum % | -66.96 | |||||
12-1 Month Momentum % | -65.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.5 | |||||
Quick Ratio | 1.75 | |||||
Cash Ratio | 0.5 | |||||
Days Inventory | 106.69 | |||||
Days Sales Outstanding | 46.52 | |||||
Days Payable | 48.04 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -93.8 | |||||
Shareholder Yield % | -15.25 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 37.97 | |||||
Operating Margin % | -12.6 | |||||
Net Margin % | -16.26 | |||||
EBITDA Margin % | -11.89 | |||||
FCF Margin % | -21.12 | |||||
OCF Margin % | -20.14 | |||||
ROE % | -84.53 | |||||
ROA % | -22.77 | |||||
ROIC % | -32.32 | |||||
3-Year ROIIC % | -103.08 | |||||
ROC (Joel Greenblatt) % | -51.86 | |||||
ROCE % | -25.95 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.1 | |||||
PB Ratio | 0.66 | |||||
Price-to-Tangible-Book | 0.66 | |||||
EV-to-EBIT | -1.58 | |||||
EV-to-EBITDA | -1.68 | |||||
EV-to-Revenue | 0.2 | |||||
EV-to-Forward-Revenue | 0.3 | |||||
EV-to-FCF | -0.95 | |||||
Price-to-GF-Value | 0.45 | |||||
Price-to-Median-PS-Value | 0.23 | |||||
| Price-to-Net-Current-Asset-Value | 1.65 | |||||
Earnings Yield (Greenblatt) % | -63.29 | |||||
FCF Yield % | -75.6 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SNOA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Sonoma Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 19.529 | ||
| EPS (TTM) ($) | -1.89 | ||
| Beta | 0.1931 | ||
| 3-Year Sharpe Ratio | -0.37 | ||
| 3-Year Sortino Ratio | -0.52 | ||
| Volatility % | 81.62 | ||
| 14-Day RSI | 40.4 | ||
| 14-Day ATR ($) | 0.060379 | ||
| 20-Day SMA ($) | 1.20725 | ||
| 12-1 Month Momentum % | -65.85 | ||
| 52-Week Range ($) | 0.8501 - 6.9199 | ||
| Shares Outstanding (Mil) | 4.79 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Sonoma Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Sonoma Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2027 | 2026-11-04 | In 98 days | ||
| First quarter earnings results for 2027 | 2026-08-07 | In 9 days | ||
| General meeting for 2026 | 2026-06-24 14:00 | 1.14 (-0.87%) | ||
| Annual report for 2026 | 2026-06-16 | 1.11 (-5.11%) | ||
| Fourth quarter earnings results for 2026 | 2026-06-16 | 1.11 (-5.11%) | ||
| Third quarter earnings results for 2026 | 2026-02-10 | 2.91 (-3.96%) | ||
| Second quarter earnings results for 2026 | 2025-11-04 | 3.78 (-4.79%) | ||
| Guidance call for 2025 | 2025-09-30 14:00 | 3.94 (-1.99%) | ||
| General meeting for 2025 | 2025-08-27 14:00 | 4.82 (+0.84%) | ||
| First quarter earnings results for 2026 | 2025-08-07 | 3.02 (+0.33%) |
Show
Entries
Sonoma Pharmaceuticals Inc Frequently Asked Questions
What is Sonoma Pharmaceuticals Inc(SNOA)'s stock price today?
The current price of SNOA is $1.14. The 52 week high of SNOA is $6.92 and 52 week low is $0.85.
When is next earnings date of Sonoma Pharmaceuticals Inc(SNOA)?
The next earnings date of Sonoma Pharmaceuticals Inc(SNOA) is 2026-08-07 Est..
Does Sonoma Pharmaceuticals Inc(SNOA) pay dividends? If so, how much?
Sonoma Pharmaceuticals Inc(SNOA) does not pay dividend.
Guru Commentaries on NAS:SNOA
No articles.
Press Release
Articles on Sonoma Pharmaceuticals Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers